GW Pharmaceuticals has played down a regional media report that certain Primary Care Trusts are not paying for prescriptions for Sativex, its spray for multiple sclerosis patients.
The company says this dates from last year, before UK approval of Sativex, when it was only available on a named-patient basis.
Under the named-patient programme, over 90% of PCTs in the UK paid for Sativex on the NHS. GW hoped that in light of formal regulatory approval in late June, such policies would continue for 'the vast majority of PCTs'.
The company added, 'It is inevitable under the PCT system in the UK that certain localities will adopt different policies towards medicines and Sativex is no different in this respect to any other medicine.
'The issue of PCT policies towards adoption of new medicines is one which GW's UK marketing partner, Bayer Schering Pharma, is accustomed to addressing and one that is common to the launch of all new medicines in the UK.'
In the short time since the launch of Sativex, NHS prescriptions were being written around the UK. GW and Bayer Schering Pharma were pleased with progress so far.
NewsHawk: Ganjarden: 420 MAGAZINE
Source: Business Financial News Wire
Contact: Business Financial News Wire
Copyright: 2010 Business Financial News Wire
Website: Most PCTs paying for Sativex, says GW Pharma
The company says this dates from last year, before UK approval of Sativex, when it was only available on a named-patient basis.
Under the named-patient programme, over 90% of PCTs in the UK paid for Sativex on the NHS. GW hoped that in light of formal regulatory approval in late June, such policies would continue for 'the vast majority of PCTs'.
The company added, 'It is inevitable under the PCT system in the UK that certain localities will adopt different policies towards medicines and Sativex is no different in this respect to any other medicine.
'The issue of PCT policies towards adoption of new medicines is one which GW's UK marketing partner, Bayer Schering Pharma, is accustomed to addressing and one that is common to the launch of all new medicines in the UK.'
In the short time since the launch of Sativex, NHS prescriptions were being written around the UK. GW and Bayer Schering Pharma were pleased with progress so far.
NewsHawk: Ganjarden: 420 MAGAZINE
Source: Business Financial News Wire
Contact: Business Financial News Wire
Copyright: 2010 Business Financial News Wire
Website: Most PCTs paying for Sativex, says GW Pharma
